28 NOVEMBER
THE NEW ZEALAND GAZETTE
5395

RESERVE BANK OF NEW ZEALAND

STATEMENT OF ASSETS AND LIABILITIES OF THE RESERVE BANK OF NEW ZEALAND AS AT THE CLOSE OF BUSINESS ON WEDNESDAY, 20 NOVEMBER 1985

Liabilities Assets
$(000) $(000)
Overseas liabilities— Overseas assets—
Denominated in overseas currencies— Denominated in overseas currencies—
(a) Short term 224,954 (a) Short term 1,370,024
(b) Long term 1,153,634 (b) Long term 12,533
Denominated in New Zealand currency— (c) Holdings of I.M.F. special drawing
(a) Short term 50,371 rights 15,795
(b) Long term .. Denominated in New Zealand currency—
1,428,959 (a) Short term 2,792
Allocation of special drawing rights by (b) Long term 699
I.M.F. 262,876 Gold ..
1,401,843
Deposits—
(a) State:
Public account 1,488,196 Advances and discounts—
Other 210,746 (a) State:
(b) Marketing organisations 162,803 Public account 1,208,150
(c) Stabilisation accounts 83,786 Other 9,709
(d) Trading banks 124,947 (b) Marketing organisations 493,558
(e) Other 19,718 (c) Stabilisation accounts ..
2,090,196 (d) Trading banks:
Notes in circulation 721,345 Compensatory deposits 5,127
Other liabilities 201,118 (e) Other 396
1,718,940
Reserves—
(a) General reserve 100,000 Term Loans—
(b) Other reserves 71,956 Marketing organisations 800,000
(c) Profit and loss appropriation account 171,956 Investments in New Zealand—
$4,876,450 (a) New Zealand Government securities 781,801
(b) Other 11,870
793,671
Other assets 161,996
$4,876,450

G. K. FROGGATT, Chief Manager, Corporate Services.

Consent to the Distribution of New Medicines

PURSUANT to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

SCHEDULE

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Diflunisal BP 250 mg Tablet Pacific Pharmaceuticals Ltd., New Zealand Ansal '250'
Isosorbide Dinitrate BP 10 mg & 30 mg Tablet Pacific Pharmaceuticals Ltd., New Zealand Coronex '10' & '30'
Magnesium Sulphate Injection David Bull Laboratories Pty Ltd., Australia -
49.3% w/v (ampoule)
Indomethacin BP 100 mg Suppository Glaxo Operations Ltd., England -
Atropine Sulphate BP Injection David Bull Laboratories Pty Ltd., Australia -
400 mcg, 600 mcg & 1.2 mg in each ml (ampoules)
Sodium Bicarbonate 8.4% w/v Injection David Bull Laboratories Pty Ltd., Australia -
(ampoule)
Edrophonium Chloride USP Injection Taylor Pharmacal Co., U.S.A. Enlon
10 mg in each ml (ampoule)
Glipizide 5 mg Tablet Farmitalia Carlo Erba, Italy Minidiab
Tolciclate 1% w/v Lotion Farmitalia Carlo Erba, Italy Tolmicen
Tolciclate 1% w/w Cream Farmitalia Carlo Erba, Italy Tolmicen
Tolciclate 0.5% w/w Powder Farmitalia Carlo Erba, Italy Soaclens
(Disodium Edetate 0.10% w/w with surface-active agent Solution Alcon Laboratories Ltd., Canada

Dated this 16th day of November 1985.

MICHAEL BASSETT, Minister of Health.

35